Immunoparalysis After Pancreaticoduodenectomy

Abroad (travel likely)Recruiting

Conditions

Pancreatic Ductal Adenocarcinoma (mPDAC) · Pancreatic Head Tumour · Pancreatic Fistula

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Julie PERINEL, Lyon, France
Contact: Study coordinator (Julie PERINEL, PHU) · julie.perinel@chu-lyon.fr · 0472116261
Xavier MULLER, Lyon, France
Contact: Study coordinator (Xavier MULLER, Dr) · xavier.muller@chu-lyon.fr · 0472118088
Aurélien DUPRE, Lyon, France
Contact: Study coordinator (Aurélien DUPRE, PU-PH) · aurelien.dupre@lyon.unicancer.fr · 0478782828
Jean-Christophe LIFANTE, Pierre-Bénite, France
Contact: Study coordinator (Jean-Christophe LIFANTE, PU-PH) · jean-christophe.lifante@chu-lyon.fr · 0478569095

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic Ductal Adenocarcinoma (mPDAC)

Abroad (travel likely)RecruitingPHASE2

La Jolla, United States

A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma

Gastric (Stomach) Cancer · GastroEsophageal Cancer · Pancreatic Ductal Adenocarcinoma (mPDAC)

Abroad (travel likely)RecruitingPHASE1

Seongnam, South Korea · Seongnam, South Korea

TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)

Pancreatic Adenocarcinoma Metastatic · Pancreatic Ductal Adenocarcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Pamplona, Spain · Barakaldo, Spain